Suppr超能文献

PUS1 是一种用于评估人类肾细胞癌恶性程度的新型生物标志物。

PUS1 is a novel biomarker for evaluating malignancy of human renal cell carcinoma.

机构信息

National Clinical Research Center for Child Health of the Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China.

Department of Urology, Third Affiliated Hospital of the Second Military Medical University, Shanghai 201805, China.

出版信息

Aging (Albany NY). 2023 Jun 13;15(11):5215-5227. doi: 10.18632/aging.204799.

Abstract

Renal cell carcinoma (RCC) is one of the most common malignancies. Despite the rapid development of the oncology research and surgical treatment, the prognosis of RCC has not significantly improved. Thus, exploration of the pathological molecular mechanism and development of new therapeutic targets of RCC are of great importance. Herein, by bioinformatic analysis and cell experiments, we report that, the expression of pseudouridine synthase 1 (PUS1), belonging to the family of PUS enzymes that participate in RNA modifications, is closely associated with RCC progression. In addition, the upregulated PUS1 expression results in the elevated RCC cancer cell viability, migration, invasion and colony formation ability, whereas the decreased PUS1 expression exerts the opposite effects on RCC cells. Thus, our findings show the potential role of PUS1 in RCC cells, providing with evidence that PUS1 is involved in RCC progression, which may help contribute to RCC diagnosis and intervention in clinic.

摘要

肾细胞癌 (RCC) 是最常见的恶性肿瘤之一。尽管肿瘤学研究和外科治疗迅速发展,但 RCC 的预后并未显著改善。因此,探索 RCC 的病理分子机制和开发新的治疗靶点非常重要。在此,我们通过生物信息学分析和细胞实验报告称,属于参与 RNA 修饰的 PUS 酶家族的假尿嘧啶合成酶 1 (PUS1) 的表达与 RCC 进展密切相关。此外,上调的 PUS1 表达导致 RCC 癌细胞活力、迁移、侵袭和集落形成能力升高,而下调的 PUS1 表达对 RCC 细胞产生相反的效果。因此,我们的研究结果表明 PUS1 在 RCC 细胞中具有潜在作用,为 PUS1 参与 RCC 进展提供了证据,这可能有助于 RCC 的诊断和临床干预。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfb1/10292901/b8b6b72a2195/aging-15-204799-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验